Aura Biosciences, Inc. (AURA)

USD 6.15

(1.32%)

Market Cap (In USD)

309.15 Million

Revenue (In USD)

-

Net Income (In USD)

-76.4 Million

Avg. Volume

262.75 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.63-12.378
PE
-3.51
EPS
-1.75
Beta Value
0.332
ISIN
US05153U1079
CUSIP
05153U107
CIK
1501796
Shares
50268757.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Elisabet de los Pinos Ph.D.
Employee Count
-
Website
https://www.aurabiosciences.com
Ipo Date
2021-10-29
Details
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.